Tilsotolimod

Summary

Tilsotolimod (CHEMBL4297838) is a phase-3 clinical-stage unknown; indicated across 4 conditions including melanoma and metastatic melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297838
Name	Tilsotolimod
Type	Unknown
Max phase	3

Also known as: IMO-2125, Tilsotolimod, TILSOTOLIMOD

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756
metastatic melanoma	3	MONDO:0005191	EFO:0002617
neoplasm	2	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	5
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03865082	PHASE2	ACTIVE_NOT_RECRUITING	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
NCT04126876	PHASE2	RECRUITING	A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
NCT02644967	PHASE2	COMPLETED	A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
NCT00728936	PHASE1	COMPLETED	Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
NCT00990938	PHASE1	COMPLETED	Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
NCT03052205	PHASE1	COMPLETED	A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
NCT04196283	PHASE1	COMPLETED	A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT04270864	PHASE1	TERMINATED	Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).